Evolus EOLS
NASDAQ EOLS
$8.35 -0.25 (-2.91%)
At close: Aug 20, 2026 · 4:00 PM EDT

Evolus (EOLS) Cash from Investing Activities (2018 - 2026)

Evolus' (EOLS) quarterly Cash from Investing Activities came in at -$1.7 million in Q1 2026, up 9.13% YoY from -$1.5 million in Q1 2025, and up 21.93% on a QoQ basis from -$2.2 million in Q4 2025.

Evolus (EOLS) Cash from Investing Activities (2018 - 2026) Analysis & Trends

Evolus (EOLS) has 9 years of Cash from Investing Activities data on file, last reported at -$1.7 million in Q1 2026.

  • Quarterly Cash from Investing Activities rose 9.13% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.3 million (down 40.68% YoY) and the FY2025 annual result came in at -$8.5 million, down 75.24% from the prior year.
  • Cash from Investing Activities grew to -$1.7 million in Q1 2026, from -$2.2 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of -$216000.0 in Q2 2023 to a low of -$2.3 million in Q2 2025.
  • A 5-year average of -$1.1 million and a median of -$1.3 million in 2024 frame the typical range for Cash from Investing Activities.
  • Annual changes were most pronounced in 2022 — Cash from Investing Activities tumbled 4380.95% — and 2023, when it soared 74.05%.
  • Tracing EOLS's Cash from Investing Activities over 5 years: stood at -$1.4 million in 2022, then soared by 74.05% to -$361000.0 in 2023, then sank by 277.29% to -$1.4 million in 2024, then slumped by 59.03% to -$2.2 million in 2025, then advanced by 21.93% to -$1.7 million in 2026.
  • The last three Cash from Investing Activities figures came in at -$1.7 million (Q1 2026), -$2.2 million (Q4 2025), and -$2.2 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Haleon 43.83 Bn 42.86 Bn - -
2 Teva Pharmaceutical Industries 42.87 Bn 39.22 Bn 2.15 Bn -491.00 Mn
3 Zoetis 31.41 Bn 29.73 Bn 1.05 Bn -300.00 Mn
4 Takeda Pharmaceutical 28.55 Bn 22.75 Bn 5.10 Bn -550.24 Mn
5 United Therapeutics 22.08 Bn 19.42 Bn 683.80 Mn 87.50 Mn
6 Viatris 18.73 Bn 17.84 Bn 1.46 Bn -51.60 Mn
7 Neurocrine Biosciences 15.44 Bn 15.05 Bn 935.80 Mn -135.40 Mn
8 Elanco Animal Health 11.75 Bn 11.22 Bn 798.00 Mn -110.00 Mn
9 Dr Reddys Laboratories 10.11 Bn 9.94 Bn - -
10 Evolus 552.49 Mn 507.32 Mn 57.18 Mn -500,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 -500,000.00
Jun 30, 2026 -500,000.00
Mar 31, 2026 -1.69 Mn
Mar 31, 2026 -1.69 Mn
Dec 31, 2025 -2.17 Mn
Dec 31, 2025 -2.17 Mn
Sep 30, 2025 -2.16 Mn
Sep 30, 2025 -2.16 Mn
Jun 30, 2025 -2.27 Mn
Jun 30, 2025 -2.27 Mn
Mar 31, 2025 -1.86 Mn
Mar 31, 2025 -1.86 Mn
Dec 31, 2024 -1.36 Mn
Dec 31, 2024 -1.36 Mn
Sep 30, 2024 -1.41 Mn
Sep 30, 2024 -1.41 Mn
Jun 30, 2024 -1.25 Mn
Jun 30, 2024 -1.25 Mn
Mar 31, 2024 -797,000.00
Mar 31, 2024 -797,000.00